Trial Profile
viite: EudraCT-numero 2005-004253-10 Tyypin 2 diabetesta sairastavien maksansiirtopotilaiden rasvamaksan hoito insuliiniherkistajalla (rosiglitatsoni)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 31 May 2011
Price :
$35
*
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Fatty liver; Hyperglycaemia
- Focus Therapeutic Use
- 31 May 2011 New trial record